Guardant Health (GH)
(Delayed Data from NSDQ)
$27.10 USD
-0.37 (-1.35%)
Updated May 31, 2024 04:00 PM ET
After-Market: $27.11 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Guardant Health (GH) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$37.47 | $50.00 | $28.00 | 36.40% |
Price Target
Based on short-term price targets offered by 17 analysts, the average price target for Guardant Health comes to $37.47. The forecasts range from a low of $28.00 to a high of $50.00. The average price target represents an increase of 36.4% from the last closing price of $27.47.
Analyst Price Targets (17)
Broker Rating
Guardant Health currently has an average brokerage recommendation (ABR) of 1.27 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 20 brokerage firms. The current ABR compares to an ABR of 1.27 a month ago based on 20 recommendations.
Of the 20 recommendations deriving the current ABR, 16 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 80% and 10% of all recommendations. A month ago, Strong Buy made up 80%, while Buy represented 10%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 16 | 16 | 16 | 15 | 15 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.27 | 1.27 | 1.27 | 1.29 | 1.29 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/24/2024 | William Blair | Andrew F Brackmann | Strong Buy | Strong Buy |
5/24/2024 | Stephens | Mason Carrico | Strong Buy | Strong Buy |
5/13/2024 | Raymond James | Andrew Cooper | Moderate Buy | Moderate Buy |
4/29/2024 | Canaccord Genuity | Kyle Mikson | Strong Buy | Strong Buy |
4/24/2024 | Craig-Hallum | William B Bonello | Not Available | Strong Buy |
4/12/2024 | SVB Securities | Puneet Souda | Strong Buy | Strong Buy |
4/5/2024 | Guggenheim Securities | Subbu Nambi | Hold | Hold |
2/27/2024 | BTIG | Mark Massaro | Strong Buy | Strong Buy |
2/26/2024 | Piper Sandler | David M Westenberg | Strong Buy | Strong Buy |
12/15/2023 | Scotiabank | Sung-Ji Nam | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.27 |
ABR (Last week) | 1.27 |
# of Recs in ABR | 20 |
Average Target Price | $37.47 |
LT Growth Rate | 32.10% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 88 of 252 |
Current Quarter EPS Est: | -0.57 |